|
DE69229221T2
(de)
*
|
1991-03-05 |
1999-09-23 |
The Wellcome Foundation Ltd., Greenford |
Expression rekombinanter proteine in attenuierten bakterien
|
|
US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
JP3308534B2
(ja)
|
1991-10-25 |
2002-07-29 |
イミュネックス・コーポレーション |
新規なサイトカイン
|
|
US5716805A
(en)
*
|
1991-10-25 |
1998-02-10 |
Immunex Corporation |
Methods of preparing soluble, oligomeric proteins
|
|
US5981724A
(en)
*
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
EP0659086B1
(en)
*
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
|
JP4242447B2
(ja)
*
|
1993-01-22 |
2009-03-25 |
イミュネックス・コーポレーション |
Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
ATE309267T1
(de)
*
|
1994-04-28 |
2005-11-15 |
Boehringer Ingelheim Pharma |
Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
|
|
CA2213798C
(en)
|
1995-03-01 |
2001-02-06 |
Immunex Corporation |
Method for stimulating an immune response
|
|
KR100453314B1
(ko)
|
1995-06-07 |
2004-12-17 |
임뮤넥스 코포레이션 |
Cd40l 돌연변이 단백질
|
|
US6713279B1
(en)
*
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
*
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
*
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
CA2313805A1
(en)
|
1997-12-19 |
1999-07-01 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
*
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
*
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
DE69939264D1
(de)
*
|
1998-09-04 |
2008-09-18 |
Emergent Product Dev Uk Ltd |
Attenuierte salmonella spi2 mutante als antigen-träger
|
|
US7300774B1
(en)
*
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
IL144952A0
(en)
|
1999-04-16 |
2002-06-30 |
Hoffmann La Roche |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
|
WO2001026608A2
(en)
*
|
1999-10-14 |
2001-04-19 |
Ledbetter Jeffrey A |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
DE60011560T2
(de)
*
|
1999-12-28 |
2005-08-18 |
Akzo Nobel N.V. |
Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
|
|
US7371392B2
(en)
*
|
2000-02-02 |
2008-05-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cd40 ligand adjuvant for respiratory syncytial virus
|
|
AU2001256957B2
(en)
*
|
2000-03-17 |
2005-08-25 |
Pharmacia & Upjohn Company Llc |
Salmonella vaccine materials and methods
|
|
GB0015426D0
(en)
*
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
WO2002036769A2
(en)
|
2000-10-31 |
2002-05-10 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
PT1407004E
(pt)
*
|
2001-05-15 |
2009-08-31 |
Ortho Mcneil Janssen Pharm |
Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas
|
|
ZA200400479B
(en)
*
|
2001-07-06 |
2006-05-31 |
Abic Biolog Lab Teva |
Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
|
|
RU2004103468A
(ru)
*
|
2001-07-06 |
2005-04-20 |
Абик Байолоджикал Лэборетериз Тева Лтд. (Il) |
Нуклеиновые кислоты, кодирующие рекомбинантный 250 к-да-антиген спорозоитов/мерозоитов eimeria maxima, и их применения
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
WO2003028441A1
(en)
|
2001-10-02 |
2003-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy for the prevention of autoimmune disease
|
|
ATE399180T1
(de)
*
|
2001-12-21 |
2008-07-15 |
Immunex Corp |
Rekombinante polypeptide
|
|
EP1487273B1
(en)
*
|
2002-02-13 |
2009-01-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US6923958B2
(en)
*
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP1499191B1
(en)
*
|
2002-04-15 |
2012-05-09 |
Washington University in St. Louis |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20050181994A1
(en)
*
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
EP1720905A2
(en)
|
2003-12-11 |
2006-11-15 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
KR101243577B1
(ko)
*
|
2004-10-07 |
2013-03-20 |
아고스 쎄라퓨틱스, 인코포레이티드 |
성숙 수지상 세포 조성물 및 그의 배양 방법
|
|
US8513008B2
(en)
*
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
SI1949913T1
(sl)
|
2005-10-07 |
2011-02-28 |
Proyecto Biomedicina Cima Sl |
Imunsko stimulacijska kombinacija za zaĺ äśito in zdravljenje hepatitisa c
|
|
US9533036B2
(en)
*
|
2005-11-07 |
2017-01-03 |
Microvax, Llc |
Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
|
|
DE102005054643B3
(de)
|
2005-11-10 |
2007-02-15 |
Assa Abloy Sicherheitstechnik Gmbh |
Schließzylinder
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
CU23576A1
(es)
*
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
*
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
FR2898905B1
(fr)
*
|
2006-03-24 |
2008-05-09 |
Rhodia Recherches & Tech |
Composition polyisocyanate a proprietes anti-chocs ameliorees
|
|
US20090246220A1
(en)
*
|
2006-08-28 |
2009-10-01 |
Ertl Hildegund C J |
Constructs for enhancing immune responses
|
|
PT2066339E
(pt)
*
|
2006-09-18 |
2014-10-31 |
Texas A & M Univ Sys |
Composições e métodos de potenciar respostas imunes
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CN101024076B
(zh)
*
|
2007-03-29 |
2010-08-18 |
中国农业大学 |
球虫的新用途
|
|
ES2560871T3
(es)
*
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
WO2009059018A1
(en)
|
2007-10-30 |
2009-05-07 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
HUE047164T2
(hu)
*
|
2007-11-01 |
2020-04-28 |
Univ Arkansas |
Kompozíciók és eljárások eimeria elleni immunválasz fokozására
|
|
JP5674155B2
(ja)
*
|
2008-07-21 |
2015-02-25 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ |
Ｔｎｆｓｆ一本鎖分子
|
|
US8316310B2
(en)
|
2008-08-05 |
2012-11-20 |
International Business Machines Corporation |
System and method for human identification proof for use in virtual environments
|
|
EP2184229B1
(en)
*
|
2008-11-11 |
2012-10-17 |
AGUSTAWESTLAND S.p.A. |
Helicopter rotor
|
|
US20100150958A1
(en)
*
|
2008-12-15 |
2010-06-17 |
Vectogen Pty Ltd. |
Methods and Compositions for Use of a Coccidiosis Vaccine
|
|
NO2525817T3
(cg-RX-API-DMAC7.html)
*
|
2010-01-21 |
2018-01-06 |
|
|
|
EP2771022B1
(en)
*
|
2011-10-11 |
2020-07-01 |
Viela Bio, Inc. |
Cd40l-specific tn3-derived scaffolds and methods of use thereof
|
|
US20140079704A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
BI-Specific Diabodies For Masking And Targeting Vaccines
|
|
WO2014070709A1
(en)
*
|
2012-10-29 |
2014-05-08 |
The Board Of Trustees Of The University Of Arkansas |
Novel mucosal adjuvants and delivery systems
|
|
EP2956165B1
(en)
*
|
2013-02-14 |
2019-09-11 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
|
|
AR095313A1
(es)
*
|
2013-03-15 |
2015-10-07 |
Univ Arkansas |
Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
|
|
MX2016016080A
(es)
*
|
2014-06-05 |
2017-05-09 |
Univ Arkansas |
Vacunas guiadas por anticuerpos y metodos de uso para generar respuestas imunitarias maduras rapidas.
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
EP3436070A4
(en)
*
|
2016-03-29 |
2019-11-27 |
University of Southern California |
AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
|
|
PT3464361T
(pt)
*
|
2016-05-27 |
2021-12-27 |
Abbvie Biotherapeutics Inc |
Anticorpos anti-cd40 e suas utilizações
|
|
EP3500585A4
(en)
*
|
2016-08-17 |
2020-04-01 |
Factor Bioscience Inc. |
NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
|